Amgen’s anticompetitive harms 'continue to deepen,' Regeneron says in amended US complaint over Praluent
MLex Summary: Amgen has made it "economically unfeasible" to sell a drug benefiting thousands of patients who suffer from high cholesterol, and anticompetitive content "described in black and white" in the...To view the full article, register now.
Already a subscriber? Click here to view full article